Gasparetto, Cristina http://orcid.org/0000-0003-1513-5605
Schiller, Gary J.
Tuchman, Sascha A.
Callander, Natalie S.
Baljevic, Muhamed
Lentzsch, Suzanne
Rossi, Adriana C.
Kotb, Rami
White, Darrell
Bahlis, Nizar J.
Chen, Christine I.
Sutherland, Heather J.
Madan, Sumit
LeBlanc, Richard
Sebag, Michael
Venner, Christopher P.
Bensinger, William I.
Biran, Noa
Ammu, Sonia
Ben-Shahar, Osnat
DeCastro, Andrew
Van Domelen, Dane
Zhou, Tianjun
Zhang, Chris
Bentur, Ohad S.
Shah, Jatin
Shacham, Sharon
Kauffman, Michael
Lipe, Brea
Funding for this research was provided by:
Karyopharm Therapeutics
Article History
Received: 14 July 2021
Accepted: 20 October 2021
First Online: 20 November 2021
Competing interests
: CG—advisory board: Karyopharm, Abbvie, Janssen, GSK, Sanofi, Oncopeptide; speaker: Karyopharm, GSK, Sanofi. GJS—research funding from Karyopharm. SAT—honoraria/advisory board: Karyopharm, Caelum, Sanofi; research funding: Karyopharm, Sanofi, Caelum; consultancy: Oncopeptides. NSC—nothing to disclose. MB—Independent Review Committee member and consultant: Karyopharm; advisory role and consultant: BMS/Celgene; advisory role: Oncopeptides, Johnson & Johnson; research support: Amgen, Exelixis. SL—consultant advisory role: Caelum Bioscience, Sorrento, Janssen, Celularity, Abbvie, GSK, Takeda, Karyopharm, Sanofi, Oncopetide; stock ownership: Caelum Bioscience, Magenta; research grant: Karyopharm, Sanofi. ACR—consultant: BMS, Celgene, Amgen, Janssen; research support: BMS, Karyopharm, Abbvie. RK—research funding: Merck, Sanofi; patents, royalties, other intellectual property: none; stock and other ownership interests: Karyopharm; consulting or advisory role: Celgene/BMS; Janssen; Amgen; Takeda; Sanofi; Merck; honoraria: none; speakers’ bureau: none; travel, accommodations, expenses: none. DW—honoraria: Amgen, Antengene, Celgene/BMS, GSK, Janssen, Karyopharm, Sanofi, Takeda. NJB—honoraria: Janssen, Celgene, Amgen, Takeda, AbbVie, GlaxoSmithKline, Sanofi, Genentech and Karyopharm; consultant/advisor role: Janssen, Celgene, Amgen, Takeda, AbbVie, GlaxoSmithKline, Karyopharm and Genentech. CIC—research funding: Gilead, BMS; consultant or advisory: BMS, Novartis, Gilead, Abbvie, Beigene. HJS—honoraria and consultant or advisory role: Amgen, Takeda, Celgene, BMS, Janssen, Sanofi-Genzyme. SM—consultant or advisory role: ad hoc advisory board for BMS, Takeda, Sanofi, Janssen, Amgen; GSK; speakers’ bureau: BMS, GSK, Takeda, Janssen, Karyopharm. RL—research funding: BMS/Celgene; consultant or advisory role: Janssen, BMS/Celgene, Amgen, Sanofi, Takeda. MS—advisory boards: Janssen, Karyopharm, Amgen, Novartis, Bristol-Myers Squibb, Takeda; no other disclosures. CPV—honoraria from BMS/Celgene, Janssen, Sanofi, GSK, Takeda. WIB—research funding: BMS, Karyopharm, Poseida, Harpoon, Regeneron, Janssen, Sanofi; consulting: Janssen, Regeneron, BMS; honoraria/speakers’ bureau: Takeda, BMS, Amgen, Janssen; no travel in the past year. NB—consultant: Karyopharm, BMS/Celgene, Sanofi, Janssen, Oncopeptides; research support: Karyopharm, BMS/Celgene, Janssen, Merck; speakers’ bureau: Oncopeptides, Janssen; advisory board: BMS/Celgene, Sanofi. SA—employee and stock holder in Karyopharm Therapeutics. OB-S—employee and stockholder in Karyopharm Therapeutics. AD—employee and stockholder in Karyopharm Therapeutics. DVD—employee and stockholder in Karyopharm Therapeutics. TZ—a former employee and stockholder in Karyopharm Therapeutics. CZ—employee and stockholder in Karyopharm Therapeutics. OSB—employee and stockholder in Karyopharm Therapeutics. JS—CMO, employee and stockholder in Karyopharm Therapeutics. SS—President, employee and stockholder in Karyopharm Therapeutics; patents and royalties: (8999996, 9079865, 9714226, PCT/US12/048319, and I574957) on hydrazide-containing nuclear transport modulators and uses, and pending patents (PCT/US12/048319, 499/2012, PI20102724, and 2012000928). MGK—CEO, employee and stockholder in Karyopharm Therapeutics. BL—advisory role: BMS, GSK, Janssen, Karyopharm.
: The study protocol was approved by the institutional review board or an independent ethics committee at each participating centre and was in accordance with the Declaration of Helsinki, the International Conference on Harmonisation-Good Clinical Practice and local laws. All patients provided written informed consent prior to enrollment.